LZAP, a putative tumor suppressor, selectively inhibits NF-kappaB.

Article Details

Citation

Wang J, An H, Mayo MW, Baldwin AS, Yarbrough WG

LZAP, a putative tumor suppressor, selectively inhibits NF-kappaB.

Cancer Cell. 2007 Sep;12(3):239-51.

PubMed ID
17785205 [ View in PubMed
]
Abstract

LZAP has been reported to inhibit cellular proliferation and clonogenic growth. Here, we report that decreased LZAP expression promoted cellular transformation, xenograft tumor growth, and xenograft tumor vascularity. Loss of LZAP also increased cellular invasion, and MMP-9 expression dependent on NF-kappaB. LZAP directly bound to RelA, impaired serine 536 phosphorylation of RelA, increased HDAC association with RelA, inhibited basal and stimulated NF-kappaB transcriptional activity, and was found at the promoter of selective NF-kappaB-responsive genes. LZAP protein levels were markedly decreased in 32% of primary HNSCCs (n = 28) and decreased LZAP levels in primary HNSCC correlated with increased expression of the NF-kappaB-regulated genes IL-8 and IkappaBalpha. In aggregate, these data support a role of LZAP in NF-kappaB regulation and tumor suppression.

DrugBank Data that Cites this Article

Polypeptides
NameUniProt ID
Transcription factor p65Q04206Details